Overview

  • Product nameAnti-BCL9L antibody
  • Description
    Rabbit polyclonal to BCL9L
  • Specificityab113110 is predicted to not cross-react with other BCL family members. At least four isoforms of BCL9L are known to exist; ab113110 will detect all four.
  • Tested applicationsSuitable for: ICC, WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat
  • Immunogen

    Synthetic peptide containing a 20 amino acid sequence from the N terminal region of Human BCL9L (NP_872363).

  • Positive control
    • HeLa cell lysate.

Properties

  • FormLiquid
  • Storage instructionsShipped at 4°C. Store at 4°C (stable for up to 12 months).
  • Storage bufferPreservative: 0.02% Sodium azide
    Constituent: 99.98% PBS
  • Concentration information loading...
  • PurityImmunogen affinity purified
  • Purification notesab113110 is purified by affinity chromatography via a peptide column.
  • ClonalityPolyclonal
  • IsotypeIgG

Associated products

Applications

Our Abpromise guarantee covers the use of ab113110 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC Use a concentration of 10 µg/ml.
WB Use a concentration of 1 - 2 µg/ml. Predicted molecular weight: 157 kDa.

Target

  • FunctionTranscriptional regulator that acts as an activator. Promotes beta-catenin transcriptional activity. Plays a role in tumorigenesis. Enhances the neoplastic transforming activity of CTNNB1.
  • Tissue specificityExpressed in breast, ductal and invasive ductal carcinomas of the breast, sporadic colorectal adenomas and carcinomas (at protein level). Expressed in fetal brain. Expressed in lung, amygdala, eye, prostate, pancreatic and prostate cancers, head and neck tumors and embryonal tumor.
  • Sequence similaritiesBelongs to the BCL9 family.
  • DomainTne C-terminal domain is important for its transactivation activity.
  • Cellular localizationNucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • B-cell CLL antibody
    • B-cell CLL/lymphoma 9-like protein antibody
    • B-cell lymphoma 9-like protein antibody
    • B9L antibody
    • BCL9-2 antibody
    • BCL9-like protein antibody
    • BCL9-related beta-catenin-binding protein antibody
    • Bcl9l antibody
    • BCL9L_HUMAN antibody
    • DLNB11 antibody
    • Nuclear co factor of beta catenin signalling antibody
    • Protein BCL9-2 antibody
    see all

Anti-BCL9L antibody images

  • All lanes : Anti-BCL9L antibody (ab113110) at 1 µg/ml

    Lane 1 : HeLa cell lysate
    Lane 2 : HeLa cell lysate with Blocking peptide


    Predicted band size : 157 kDa
  • Immunocytochemistry of Bcl9L in HeLa cells with ab113110 at 10 ug/mL.

References for Anti-BCL9L antibody (ab113110)

ab113110 has not yet been referenced specifically in any publications.

Product Wall

Application Western blot
Sample Mouse Cell lysate - whole cell (4T1 - mouse breast cancer cell line)
Gel Running Conditions Reduced Denaturing (4-12%)
Loading amount 30 µg
Specification 4T1 - mouse breast cancer cell line
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 23°C
Username

Abcam user community

Verified customer

Submitted May 12 2016

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"